Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Firebrick Pharma Limited ( (AU:FRE) ) has issued an update.
Firebrick Pharma Limited announced that its patent for Nasodine Nasal Spray, used in COVID-19 prevention, has been granted in Australia. This patent, which extends to the US, Europe, South Africa, and Mexico, provides strong commercial protection for Nasodine by covering its use in reducing viral load and preventing infection, with the patent expiring in 2040.
More about Firebrick Pharma Limited
Firebrick Pharma is a pharmaceutical innovator focused on developing and commercializing novel formulations and uses of povidone-iodine (PVP-I). The company has developed Nasodine Nasal Spray and is expanding its market presence in the United States, Singapore, Fiji, and the South Pacific, with plans to launch in the Philippines in 2026.
Average Trading Volume: 93,735
Technical Sentiment Signal: Buy
For an in-depth examination of FRE stock, go to TipRanks’ Overview page.